AVEO - AVEO Pharmaceuticals / AVEO Oncology - Stock Price & Catalysts • BiopharmIQ

BiopharmIQ

Try Pro Free Already have an account? Login

Enterprise Value

482.7M

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

2.36%

Insider Ownership

0.19%

Institutional Own.

34.47%

Qtr Updated

09/30/22

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FOTIVDA (Tivozanib) (VEGFR 123 TKI) Details Kidney cancer, Carcinoma , Genetic disorder, Rare genetic disease, Renal cell carcinoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FOTIVDA (tivo) + OPDIVO (nivolumab) Details Solid tumor/s, Renal cell carcinoma, Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ficlatuzumab (HGF MAb) Details Head and neck cancer, Head and neck squamous cell carcinoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tivozanib (FOTIVDA®) + IMFINZI® (durvalumab) Details HCC (Hepatocellular Carcinoma) (Untreated Metastatic)	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.